Jaguar Health Announces FDA Activation Of Third-Party Investigational New Drug Application For Evaluation Of Crofelemer For Treatment Of Uncontrolled Diarrhea In Patient With Short Bowel Syndrome
Portfolio Pulse from Happy Mohamed
Jaguar Health (NASDAQ:JAGX) announced the activation of a physician-requested Investigational New Drug (IND) application by the FDA to evaluate crofelemer for treatment of uncontrolled diarrhea in a patient with short bowel syndrome (SBS). The trial is supported by Napo Pharmaceuticals, a Jaguar company. Crofelemer has been granted Orphan Drug Designation (ODD) by the FDA and the European Medicines Agency (EMA) for SBS and microvillus inclusion disease (MVID).
August 01, 2023 | 1:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The FDA's activation of the IND application for Jaguar Health's drug crofelemer could potentially lead to a new treatment option for SBS patients, which may positively impact the company's stock.
The FDA's activation of the IND application for crofelemer is a positive development for Jaguar Health. If the drug proves to be effective in treating uncontrolled diarrhea in SBS patients, it could lead to increased revenues for the company, which would likely have a positive impact on the company's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100